Terralpha harnesses ADVA TeraFlex™ for 600G transport throughout France
27.1.2022 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Terralpha has deployed its FSP 3000 TeraFlex™ terminal to transport data at speeds up to 600Gbit/s between cities across France. The solution enables Terralpha – the new service provider arm of France’s SNCF railway group – to use its spare fiber capacity to offer low-latency, ultra-high-speed connectivity to customers. Now, enterprises, mobile network operators and government institutions can leverage flexible, highly reliable services for edge computing and 5G applications. What’s more, Terralpha’s network will enable homes and businesses in many underserved areas to access next-generation broadband and mobile connectivity. The new solution also features ADVA’s FSP 3000 OLS, flexgrid multi-degree ROADMs, its ALM fiber monitoring technology and its Ensemble Controller network management and control solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005706/en/
ADVA’s TeraFlex™ technology is helping Terralpha to drive 600G connectivity throughout France. (Photo: Business Wire)
“With around 20,000km of fiber deployed alongside our railway infrastructure, we knew we were in a unique position to offer super-fast connectivity right across France. What we needed was a transport solution with the capacity, flexibility and scale to match our ambitions and a partner we could trust. In ADVA, we have a European technology provider with a wealth of experience and an excellent track record for success,” said Gabriel Chenevoy, CEO of Terralpha. “The ADVA team has worked with us to deliver a solution that maximizes the value of our existing network and empowers us to provide our customers with a new level of bandwidth capacity and service quality. Our backbone infrastructure will be key to closing the digital divide by delivering high-speed services in a highly efficient and sustainable way to around 100 tier 3 cities within two years. The performance of ADVA’s equipment combined with our straight and diverse routes has enabled us to reduce actual latencies between major cities in France from 10% to 40%, supporting new latency-sensitive applications.”
The ADVA FSP 3000 TeraFlex™ terminal is specifically designed to inject enormous capacity into deployed networks without operators having to spend significant amounts on overhauling their infrastructure. With its software-defined fractional QAM modulation and adaptive baud rate capabilities, the low-power 1RU terminal is now ensuring optimal spectrum utilization in Terralpha’s transport system. The network is managed by ADVA’s Ensemble Controller, which supports programmatic SDN control, further improving efficiency by reducing troublesome and time-consuming manual processes. The infrastructure is also continuously assured by ADVA’s ALM fiber monitoring technology with precise fault localization from Ensemble Fiber Director. This enables Terralpha’s maintenance teams to quickly detect and pinpoint any degradation in the fiber plant and resolve issues before services are affected.
“We’re helping Terralpha to unlock the full value of its fiber assets. By harnessing our technology and the expertise of our engineers, Terralpha can take advantage of its vast network architecture to bring reliable, low-latency services at unprecedented speeds to homes, businesses and service provider customers in every corner of France,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “One of the keys to the success of this project has been our close collaboration with the Terralpha team to make sure the new solution meets their exact requirements. That’s helped us deliver a turnkey solution that works seamlessly with Terralpha’s existing network to provide optimal performance over every single link. With our scalable technology and continuing support, there’s no limit to what Terralpha can achieve.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Terralpha
Incorporated in 2021, Terralpha, a 100% subsidiary of SNCF Réseau, offers Ultra High Speed data transport services. Its DNA “Ultra High Speed for all territories” is supported by an ambition to deploy Ultra High Speed and high reliability points of presence throughout France. The choice of architecture and transmission equipment, of European origin, enables to create circuits between cities at speeds of 100Gb/s to 600Gb/s at very low latency.
Terralpha’s mission is to ensure the trusted routing of data traffic through fully owned active and passive infrastructure. Additionally, and in order to facilitate the development of regional data centers, Terralpha offers a range of hosting solutions called ”Digital Tiles” to host the equipment necessary for the storage and the processing of information locally. Each of these “Digital Tiles” has a dual fiber connection to the Terralpha network, and to the public networks to meet the strategic requirements of data centers. www.terralpha.fr
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005706/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
For Terralpha press:
Hervé Legay
t +33 1 84 21 15 07
contact@terralpha.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
